Skip to main content
. 2020 Sep 18;14(11):2727–2743. doi: 10.1002/1878-0261.12790

Fig. 3.

Fig. 3

Kaplan–Meier curves with numbers at risk for OS for (A) TMB‐high, TMB‐median and TMB‐low, (B) TMB‐high and TMB‐median/low, (C) CI‐high, CI‐median, and CI‐low, and (D) CI‐median and CI‐high/low. (A, B) TMB was defined as number of mutations/Mb into low (0–1.5, N = 22), median (1.6–2.9, N = 65), and high (≥ 3.0, N = 12). Total N = 99. (A) TMB‐high vs. TMB‐median and low had a significantly worse median OS of 10.4 months (95% CI: 5.7–15.1) vs. 16.5 months (95% CI: 13.4–19.7) and 20.9 months (95% CI: 16.7–25.1), respectively (P = 0.011). (B) Groups were segregated into TMB‐high (N = 10) vs. TMB‐low/median (N = 89). A statistically significant difference remained with median OS of 18.0 months (95% CI: 14.8–21.2) in the combined group (P = 0.003) and with a HR calculated using a Cox regression analyses of 0.29 (95% CI: 0.14–0.61, P = 0.001) in TMB‐median/low vs. TMB‐high, respectively. (C, D) CI was split into low (0–7 SCA, N = 35), median (8–15 SCA, N = 42), and high (> 15 SCA or aneuploid background, N = 27). Total N = 104. (C) CI‐median vs. CI‐high and CI‐low had a worse median OS of 14.8 months (95% CI: 21.5–17.1) vs. 16.5 months (95% CI: 8.1–24.9) and 20.9 months (95% CI: 16.0–25.8), respectively. Results were borderline significant (P = 0.094). (D) Groups were then segregated into CI‐median vs. CI‐high/low with a median OS of 18.7 months in the combined group (95% CI: 13.8–23.7; P = 0.034). (E) All patients and TMB, CI, and MGMT status, ranged with highest survival first.